CJC-1295 / Ipamorelin Stack vs GHRP-2
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
CJC-1295 / Ipamorelin Stack
The CJC-1295 (without DAC) and Ipamorelin combination is the most widely researched and community-validated growth hormone secretagogue stack. By pairing a GHRH analog with a selective GHRP, the two peptides act synergistically — producing GH pulses significantly larger than either compound alone, while maintaining a physiological pulse pattern and minimal side effects.
Full profileGHRP-2
GHRP-2 is a synthetic hexapeptide that acts as a ghrelin mimetic, stimulating the pituitary gland to secrete growth hormone (GH). It is one of the most potent GH secretagogues studied, producing stronger GH pulses than GHRP-6 with comparatively less appetite stimulation.
Full profile| CJC-1295 / Ipamorelin Stack | GHRP-2 | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | CJC-1295 Ipamorelin, Mod GRF 1-29 Ipamorelin, CJC Ipa stack, CJC-1295 without DAC with Ipamorelin, GHRH GHRP combination | Growth Hormone Releasing Peptide-2, Pralmorelin, KP 102 |
| Evidence | FDA-approved | Preclinical only |
| Dosing range | 100mcg each–300mcg each mcg, once daily before sleep (or 2–3x daily for more aggressive protocols) | 100mcg–300mcg mcg, 1–3 times daily, on an empty stomach |
| Administration | Subcutaneous injection (both compounds), Administered together in the same injection | Subcutaneous injection, Intramuscular injection |
| Key side effects | Water retention (mild, common), Tingling or numbness in hands/feet (transient), Headache (usually first 1–2 weeks), Fatigue or increased sleepiness (often desired at night dose) | Increased hunger (less than GHRP-6), Elevated cortisol and prolactin at high doses, Water retention, Injection site irritation |
| Cited sources | 2 references | 3 references |
Key differences
- Evidence level differs: CJC-1295 / Ipamorelin Stack is fda-approved, while GHRP-2 is preclinical only.
- Administration: CJC-1295 / Ipamorelin Stack — Subcutaneous injection (both compounds), Administered together in the same injection; GHRP-2 — Subcutaneous injection, Intramuscular injection.
- Frequency: CJC-1295 / Ipamorelin Stack is typically once daily before sleep (or 2–3x daily for more aggressive protocols); GHRP-2 is 1–3 times daily, on an empty stomach.
- Research depth: this profile cites 2 sources for CJC-1295 / Ipamorelin Stack vs 3 for GHRP-2.
How each works
CJC-1295 / Ipamorelin Stack
CJC-1295 without DAC (Mod GRF 1-29) stimulates GHRH receptors on the pituitary, increasing the amplitude of GH pulses. Ipamorelin independently triggers GH release via the ghrelin receptor (GHS-R1a) with high selectivity — minimal cortisol, prolactin, or aldosterone co-elevation. The combination exploits two separate receptor pathways to produce synergistic GH output. Animal and human studies on each compound individually confirm GH and IGF-1 elevation. The combination is extrapolated from mechanistic research and is the most studied protocol in the peptide research community.
GHRP-2
GHRP-2 has been extensively studied in both animal and human subjects. Clinical trials have demonstrated significant GH elevation in healthy adults, with a peak GH pulse occurring 15–30 minutes post-injection. Studies show it increases IGF-1 levels with chronic use and may have mild cardioprotective properties. Unlike GHRP-6, it has a lower propensity to stimulate cortisol and prolactin at standard doses.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.